EUVIMEDEUVIMED entdecken
Open Access

Yield on Reinterpretation of Genetic Variants in Pediatric Cardiomyopathy

Takanori Suzuki iD, Robert Lesurf iD, Rajadurai Akilen, Xiaoqiao Xu, Eva Maria Batke iD, Vinay J Rao, Rebekah Jobling iD, Laura Zahavich iD, Natasha Henden iD, Jodie Ingles iD, Edgardo Alania Torres iD, Keiichi Hirono iD und 4 weitere

Journal of the American Heart Association · 16.09.2025 · 14 (18)

DOI: 10.1161/jaha.125.041298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 16.09.2025. Verfasst von Takanori Suzuki und 15 weiteren Autor:innen. Beteiligte Einrichtung: Genetics and Genome Biology Program The Hospital for Sick Children Toronto Ontario Canada. Hauptthemen laut MEDLINE: Cardiomyopathies, Genetic Testing, Genetic Variation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Variant interpretation can change over time as new knowledge emerges. Our aim was to determine the frequency and causes of variant reinterpretation on systematic reevaluation in pediatric patients with cardiomyopathy.

Methods

Overall, 227 unrelated pediatric patients with cardiomyopathy enrolled in the Heart Centre Biobank harbored a pathogenic/likely pathogenic (P/LP) variant or a variant of uncertain significance (VUS) on clinical genetic testing (2005–2022). Variant pathogenicity was reevaluated using the American College of Medical Genetics and Genomics guidelines. Additional extension cohorts (n=4547, cases) were analyzed to assess variant burden in cases versus controls (gnomAD 4.1.0).

Results

A total of 382 variants (110 P/LP, 272 VUS) in 227 patients were reevaluated. Forty‐nine variants in 49 patients (21.6%) changed classification. Twelve (10.9%) P/LP variants were downgraded to VUS in 14 patients. Leading criteria were high population allele frequency and variant not located in mutational hotspot or critical functional gene domain. Thirty‐seven (13.6%) VUS were upgraded to P/LP in 35 patients. Leading criteria were variant location in mutational hotspot for gene and deleteriousness on in silico prediction. Only 8 reclassified variants had been reported back by the clinical genetic testing laboratory at the time of the study. Ten of the 37 VUS upgraded to P/LP were significantly enriched in cardiomyopathy cases (n=4796) versus controls.

Conclusions

One in 5 patients with cardiomyopathy had a clinically relevant change in variant pathogenicity on systematic reevaluation that would require modifying family clinical screening and cascade genetic testing. These findings underscore the clinical importance of regular variant reinterpretation on follow‐up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomyopathiesGenetic TestingGenetic VariationHumansFemaleMaleChildChild, PreschoolAdolescentInfantGenetic Predisposition to DiseaseGene FrequencyMutationPhenotype

Stichwörter der Autor:innen

cardiomyopathygenetic testingpathogenic variantsvariant reinterpretationvariants of uncertain significance

Autor:innen und Institutionen

  • Genetics and Genome Biology Program The Hospital for Sick Children Toronto Ontario Canada.
  • The Centre for Computational Medicine The Hospital for Sick Children Toronto Ontario Canada.
  • Department of Internal Medicine III (Cardiology, Angiology, and Pneumology), Heidelberg University Hospital Heidelberg Germany.
  • German Center for Cardiovascular Research Partner Site Heidelberg/Mannheim Heidelberg Germany.
  • Cardiovascular Development and Disease Mechanisms, Institute for Stem Cell Science and Regenerative Medicine (DBT-inStem) Bengaluru India.
  • The University of Trans-Disciplinary Health Sciences and Technology Bangalore India.

ORCID-Profile: Takanori Suzuki, Robert Lesurf, Eva Maria Batke, Rebekah Jobling, Laura Zahavich, Natasha Henden, Jodie Ingles, Edgardo Alania Torres, Keiichi Hirono, Nathalie Roux-Buisson, Christoph Sandmann, Seema Mital

Zitieren

APA

Suzuki, T., Lesurf, R., Akilen, R., Xu, X., Batke, E. M., Rao, V. J., Jobling, R., Zahavich, L., Henden, N., Ingles, J., Torres, E. A., Hirono, K., Roux-Buisson, N., Dhandapany, P. S., Sandmann, C., & Mital, S. (2025). Yield on Reinterpretation of Genetic Variants in Pediatric Cardiomyopathy. Journal of the American Heart Association, 14(18). https://doi.org/10.1161/jaha.125.041298

Vancouver

Suzuki T, Lesurf R, Akilen R, Xu X, Batke EM, Rao VJ, et al. Yield on Reinterpretation of Genetic Variants in Pediatric Cardiomyopathy. Journal of the American Heart Association. 2025;14(18). doi:10.1161/jaha.125.041298

BibTeX
@article{Suzuki2025,
  author = {Suzuki, Takanori and Lesurf, Robert and Akilen, Rajadurai and Xu, Xiaoqiao and Batke, Eva Maria and Rao, Vinay J and Jobling, Rebekah and Zahavich, Laura and Henden, Natasha and Ingles, Jodie and Torres, Edgardo Alania and Hirono, Keiichi and Roux-Buisson, Nathalie and Dhandapany, Perundurai S and Sandmann, Christoph and Mital, Seema},
  title = {Yield on Reinterpretation of Genetic Variants in Pediatric Cardiomyopathy},
  journal = {Journal of the American Heart Association},
  year = {2025},
  volume = {14},
  number = {18},
  doi = {10.1161/jaha.125.041298}
}
Kostenlos starten →